Last reviewed · How we verify
Genovate Biotechnology Co., Ltd., — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Abilify (aripiprazole) | Abilify (aripiprazole) | marketed | Atypical antipsychotic | Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist) | Psychiatry / Neurology | |
| Combigan Ophthalmic Solutiom | Combigan Ophthalmic Solutiom | marketed | Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist | Alpha-2 adrenergic receptors and beta-adrenergic receptors | Ophthalmology | |
| Nidadd | Nidadd | phase 3 | Other |
Therapeutic area mix
- Ophthalmology · 1
- Other · 1
- Psychiatry / Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Acacia Pharma Ltd · 1 shared drug class
- Alexza Pharmaceuticals, Inc. · 1 shared drug class
- Alkermes, Inc. · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Benaroya Research Institute · 1 shared drug class
- BioXcel Therapeutics Inc · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Genovate Biotechnology Co., Ltd.,:
- Genovate Biotechnology Co., Ltd., pipeline updates — RSS
- Genovate Biotechnology Co., Ltd., pipeline updates — Atom
- Genovate Biotechnology Co., Ltd., pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Genovate Biotechnology Co., Ltd., — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genovate-biotechnology-co-ltd. Accessed 2026-05-16.